Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments

Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments

<i>Aggressive-variant prostate cancers</i> (AVPCs) are a subset of metastatic castrate-resistant prostate cancers (mCRPCs) characterized by defects in ≥ two of three of <i>TP53</i>, <i>RB1</i>, and <i>PTEN</i> (AVPCm), a profile linked to lineage plast...

Full description

Bibliographic Details
Main Authors: Paul V. Viscuse, Rebecca S. Slack-Tidwell, Miao Zhang, Prih Rohra, Keyi Zhu, F. Anthony San Lucas, Eric Konnick, Patrick G. Pilie, Bilal Siddiqui, Christopher J. Logothetis, Paul Corn, Sumit K. Subudhi, Colin C. Pritchard, Rama Soundararajan, Ana Aparicio
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
aggressive-variant prostate cancer
immunohistochemistry
molecular biomarker
next-generation sequencing
Online Access:https://www.mdpi.com/2072-6694/15/24/5843

Internet

https://www.mdpi.com/2072-6694/15/24/5843

Similar Items